Iopidine 10 mg/ml øjendråber, opløsning Данска - Дански - Lægemiddelstyrelsen (Danish Medicines Agency)

iopidine 10 mg/ml øjendråber, opløsning

essential pharma limited - apraclonidinhydrochlorid - øjendråber, opløsning - 10 mg/ml

Tomahawk 200 EC Emulsionskoncentrat Данска - Дански - SEGES Landbrug & Fødevarer

tomahawk 200 ec emulsionskoncentrat

adama northern europe b.v. - fluroxypyr - emulsionskoncentrat - 200 g/l fluroxypyr

Cleave Данска - Дански - Adama

cleave

adama - florasulam 2,5 g/l + fluroxypyr 100 g/l (10.7 % w/w) - herbicider

Mixin Данска - Дански - Adama

mixin

adama - florasulam 2,5 g/l + fluroxypyr 100 g/l (10.7 % w/w) - herbicider

Tomahawk Данска - Дански - Adama

tomahawk

adama - 200 g/l fluroxypyr - herbicider

Cleave Suspoemulsion Данска - Дански - SEGES Landbrug & Fødevarer

cleave suspoemulsion

adama northern europe b.v. - florasulam, fluroxypyr - suspoemulsion - 2,5 g/l florasulam ; 100 g/l fluroxypyr

Tomahawk 180 EC Emulsionskoncentrat Данска - Дански - SEGES Landbrug & Fødevarer

tomahawk 180 ec emulsionskoncentrat

adama northern europe b.v. - fluroxypyr - emulsionskoncentrat - 180 g/l fluroxypyr

Xtandi Европска Унија - Дански - EMA (European Medicines Agency)

xtandi

astellas pharma europe b.v. - enzalutamide - prostatiske neoplasmer - endokrine terapi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.